Recce Pharmaceuticals (ASX:RCE) has confirmed its completion of the latest fast-infusion study using its R327 anti-infective as an IV drug.
Notably, this time, the company has wrapped up a test that saw the fastest infusion times to date yet tested on patients.
The company touts its flagship R327 as an alternative antibiotic treatment (“anti-infective”) with a wide range of applications. Today’s news relates to a Urinary Tract Infection (UTI) trial, but the company is also exploring the use of the compound on post-diabetic surgery wound infections.
Six patients took place in the latest fast-infusion trial with recipients being dosed with 4000mg via IV drip.
The value proposition behind these trials is that infusion took only 20 minutes – a far cry from the first trials which took far longer. The company is, in short, seeing how quickly it can fill someone up with R327 – and kill off UTI in a one-dose sitting.
To this end, a safety committee will now review the latest (and pre-existing) trial data towards producing a report outlining the product’s risks, if any are detected. These procedures are required for full-fledged greenlight down the line.
That committee is set to report back within six weeks.
“We have successfully reached a new milestone in this trial by administering a 4,000mg dose over a fast 20-minute infusion to all subjects, the highest dosage achieved so far in this clinical trial,” Recce CEO James Graham said.
“This is a significant step forward in bringing us closer to establishing R327 as a leading treatment for those suffering from UTI/Urosepsis.”
RCE last traded at 57cps.